Bluejay Diagnostics (NASDAQ:BJDX) vs. Tactile Systems Technology (NASDAQ:TCMD) Financial Contrast

Bluejay Diagnostics (NASDAQ:BJDX) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Bluejay Diagnostics and Tactile Systems Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1	0	0	0	1.00
Tactile Systems Technology	0	2	4	1	2.86

Tactile Systems Technology has a consensus price target of $38.60, suggesting a potential upside of 46.55%. Given Tactile Systems Technology’s stronger consensus rating and higher probable upside, analysts plainly believe Tactile Systems Technology is more favorable than Bluejay Diagnostics.

Institutional & Insider Ownership

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 2.1% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Bluejay Diagnostics and Tactile Systems Technology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.39
Tactile Systems Technology	$329.52 million	1.80	$19.09 million	$0.88	29.93

Tactile Systems Technology has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bluejay Diagnostics and Tactile Systems Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Tactile Systems Technology	5.91%	9.70%	7.53%

Risk and Volatility

Bluejay Diagnostics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Tactile Systems Technology beats Bluejay Diagnostics on 14 of the 14 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About Tactile Systems Technology

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.